azd0530 + paclitaxel

**AZD0530 + paclitaxel** is a combination therapy being evaluated primarily for the treatment of advanced solid tumors and ovarian cancer. AZD0530 (saracatinib) is a potent, selective oral inhibitor of Src tyrosine kinase, a non-receptor protein kinase involved in cellular processes such as proliferation, adhesion, migration, and tumor metastasis. Paclitaxel is an established anti-microtubule chemotherapeutic agent that stabilizes microtubules and promotes apoptosis in rapidly dividing cells. This combination aims to utilize the complementary actions of an anti-mitotic agent and a targeted kinase inhibitor to enhance anti-tumor efficacy or reverse drug resistance in various solid malignancies. Clinical studies demonstrate acceptable toxicity for saracatinib (AZD0530) doses up to 175 mg daily in combination with paclitaxel, with ongoing investigation into its therapeutic potential for cancers such as ovarian, breast, and other solid tumors[1][7][5][2].

Brand names

Taxol

Other names

NSC 735464NSC735464NSC-735464saracatinib + paclitaxel